Showing 101-110 of 354 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Harnessing insulin signaling in β-cells to counter type 1 diabetes | Joslin Diabetes Center Inc. | Namrata Shukla | Cures | 01-March-2024 to 28-February-2027 | $216,326.98 |
| Targeting RNLS for Type 1 Diabetes Therapy | Joslin Diabetes Center Inc. | Peng Yi | Cures | 01-June-2025 to 31-May-2028 | $1,349,997.00 |
| Innovation Partnership | LabCentral | Luke Wallrich | Cures | 15-May-2026 to 31-May-2027 | $200,000.00 |
| Assessment of NovoSphere™ Hydrogel Encapsulation to Enable High-Loading and Extended Release of Tegoprubart for Subcutaneous Administration | Likarda, Inc | Lisa Stehno-Bittel | Cures | 15-June-2026 to 15-December-2026 | $301,200.00 |
| Transcriptional memory in human islet organogenesis | Lundquist Institute for Biomedical Medical Innovation at Harbor‐UCLA Medical Center (The Lundquist Institute) | Eiji Yoshihara | Cures | 01-April-2022 to 31-March-2027 | $749,995.50 |
| INHALE-1st: Technosphere Insulin (Afrezza®) In Combination With Basal Insulin For Youth With Newly-Diagnosed Type 1 Diabetes | Mannkind | Ian Buckner | Improving Lives | 25-June-2026 to 24-June-2028 | $600,000.00 |
| The T1D Parent Check-In: A Preventative Intervention | Massachusetts General Hospital | Ellen O’Donnell | Improving Lives | 01-July-2023 to 01-September-2026 | $390,792.17 |
| Understanding common tissue tolerance mechanisms in autoimmunity | Massachusetts General Hospital | Gary Reynolds | Cures | 01-September-2025 to 28-February-2027 | $150,000.00 |
| Epithelial Immune Sentinels in T1D Autoimmune Kidney Disease | Massachusetts General Hospital | Maria Agustina Battistone | Improving Lives | 01-September-2026 to 31-August-2028 | $189,099.97 |
| Development and testing of protease-resistant CXCL12 loaded sub 100 micron polymeric microbeads to enable alloislet transplantation without systemic immune suppression in established murine models of type 1 diabetes | Massachusetts General Hospital | Mark Poznansky | Cures | 01-February-2026 to 31-January-2028 | $599,448.76 |